Last news
U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Notified -...

The Go-No-Go (GNG) Machine is Named by DUPR, Pickleballtournaments.com and The UPA-A as the Official and Exclusive On-Site Deflection Testing Device for Professional and Amateur Tours Across the Globe

The Go-No-Go (GNG) Machine is Named by DUPR, Pickleballtournaments.com and The UPA-A as the Official and Exclusive On-Site Deflection Testing Device for Professional and Amateur Tours Across the Globe

Notified -...

Yachting: Five years of sustainable innovation at Yacht Club de Monaco, Rendezvous set for September 21-22

Yachting: Five years of sustainable innovation at Yacht Club de Monaco, Rendezvous set for September 21-22

Notified -...

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

Notified -...

First LLM with Infinite Context Attention is here, wiping out $1.2 billion RAG market value by allowing AI to live outside the Matrix

First LLM with Infinite Context Attention is here, wiping out $1.2 billion RAG market value by allowing AI to live outside the Matrix

Notified -...

TYLin Group Announces Strategic Leadership Appointment - Jenni Roseleip as Chief Marketing Officer

TYLin Group Announces Strategic Leadership Appointment - Jenni Roseleip as Chief Marketing Officer

Notified -...

WeightWatchers Appoints SoulCycle Co-Founder Julie Rice as Chief Experience Officer to Lead Community and Brand Innovation

WeightWatchers Appoints SoulCycle Co-Founder Julie Rice as Chief Experience Officer to Lead Community and Brand Innovation

Notified -...

Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia

Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia

Notified -...

1 2 3 4 5 6 7 8 9 10 ... 858
menu
menu